隐丹参酮可能具有诱导人肝癌HepG2细胞铁死亡的作用
Cryptotanshinone May Induce Ferroptosis of Human Liver Cancer HepG2 Cells
查看参考文献26篇
|
文摘
|
目的观察隐丹参酮在人肝癌HepG2细胞铁死亡中的作用。方法体外培养HepG2细胞,采用CCK-8法检测细胞活力并计算半数抑制浓度(IC_(50)),倒置相差显微镜观察细胞形态,DCFH-DA探针检测活性氧(ROS)水平变化,谷胱甘肽(GSH)测定试剂盒检测GSH水平变化,Western blot法检测铁死亡相关蛋白胱氨酸谷氨酸逆转运体轻链蛋白(xCT)和谷胱甘肽过氧化物酶4(GPX4)蛋白表达。以铁死亡抑制剂Ferrostain-1(Fer-1) 、铁螯合剂去铁胺(DFO) 、 ROS清除剂乙酰半胱氨酸(NAC)进行干预,同样检测细胞活力、ROS水平、GSH水平及xCT和GPX4表达。结果隐丹参酮可显著抑制HepG2细胞活力,并引起HepG2细胞形态学变化和死亡,IC_(50)为93.73 μmol/L。隐丹参酮可显著诱导HepG2细胞ROS累积,降低GSH水平,并下调xCT和GPX4表达。Fer-1、DFO、NAC均可不同程度恢复隐丹参酮引起的HepG2细胞活力下降。Fer-1可抑制隐丹参酮诱导的ROS累积,并恢复GSH水平及xCT和GPX4表达。结论隐丹参酮可能通过抑制GPX4和xCT表达使HepG2细胞中ROS累积,导致细胞发生铁死亡。 |
|
其他语种文摘
|
Objective To observe the effect of cryptotanshinone on the ferroptosis of human liver cancer HepG2 cells. Methods The viability of the HepG2 cells cultured in vitro was determined using the Cell Counting Kit-8 (CCK-8),and the half maximal inhibitory concentration (IC_(50)) was calculated. The cell morphology was observed using an inverted microscope. The reactive oxygen species (ROS) level was detected with the 2’, 7’-dichlorodihydrofluorescein diacetate (DCFH-DA) probe. The glutathione (GSH) assay kit was used to determine the GSH level. Western blot analysis was employed to detect the expression of cystine/glutamate antiporter system light chain (xCT) and glutathione peroxidase 4 (GPX4), two marker proteins in ferroptosis. Additionally,the cell viability,ROS level,GSH level,and the expression levels of xCT and GPX4 were detected for the cells treated with the ferroptosis inhibitor ferrostain-1 (Fer-1),the iron chelator deferoxamine (DFO),and the ROS scavenger N-acetylcysteine (NAC). Results Cryptotanshinone significantly inhibited the cell viability of HepG2 cells with an IC_(50) of 93.73 μmol/L,and caused the morphological changes and death of the cells. It could significantly induce ROS accumulation,reduce GSH level,and down-regulate the expression of xCT and GPX4 in HepG2 cells. Fer-1,DFO,and NAC can remedy the cryptotanshinone-caused decrease in the cell viability of HepG2 cells. Fer-1 could inhibit cryptotanshinone-induced ROS accumulation, restore GSH level,and recover the expression of xCT and GPX4. Conclusion Cryptotanshinone may increase the accumulation of ROS by inhibiting the expression of xCT and GPX4 to induce the ferroptosis of HepG2 cells. |
|
来源
|
中国医学科学院学报
,2021,43(3):366-370 【核心库】
|
|
DOI
|
10.3881/j.issn.1000-503X.13115
|
|
关键词
|
隐丹参酮
;
肝癌
;
铁死亡
;
细胞活力
|
|
地址
|
1.
牡丹江医学院附属红旗医院肝病及感染性疾病科, 黑龙江, 牡丹江, 157011
2.
牡丹江医学院药学院, 黑龙江, 牡丹江, 157011
3.
牡丹江医学院附属红旗医院临床药学部, 黑龙江, 牡丹江, 157011
|
|
语种
|
中文 |
|
文献类型
|
研究性论文 |
|
ISSN
|
1000-503X |
|
学科
|
肿瘤学 |
|
基金
|
黑龙江省卫生计生委科研基金
|
|
文献收藏号
|
CSCD:7009044
|
参考文献 共
26
共2页
|
|
1.
Akinyemiju T. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015.
JAMA Oncol,2017,3(12):1683-1691
|
被引
34
次
|
|
|
|
|
2.
Bertuccio P. Global trends and predictions in hepatocellular carcinoma mortality.
J Hepatol,2017,67(2):302-309
|
被引
20
次
|
|
|
|
|
3.
Liu C Y. Treatment of liver cancer.
Cold Spring Harb Perspect Med,2015,5(9):a021535
|
被引
16
次
|
|
|
|
|
4.
Petrick J L. The changing epidemiology of primary liver cancer.
Curr Epidemiol Rep,2019,6(2):104-111
|
被引
5
次
|
|
|
|
|
5.
顾欢. 中医药调控自噬治疗肝癌的研究现状.
临床肝胆病杂志,2019,35(11):2582-2587
|
被引
2
次
|
|
|
|
|
6.
徐菲. 中药复方防治肝癌作用机制研究进展.
中国实验方剂学杂志,2019,25(24):196-204
|
被引
12
次
|
|
|
|
|
7.
曾金. 隐丹参酮的药理作用研究进展.
中成药,2015,37(6):1309-1313
|
被引
17
次
|
|
|
|
|
8.
Li S. Cryptotanshinone inhibits breast cancer cell growth by suppressing estrogen receptor signaling.
Cancer Biol Ther,2015,16(1):176-184
|
被引
3
次
|
|
|
|
|
9.
Wang H. Cryptotanshinone inhibits lung cancer invasion via microRNA-133a/matrix metalloproteinase 14 regulation.
Oncol Lett,2019,18(3):2554-2559
|
被引
1
次
|
|
|
|
|
10.
Chen Z. Cryptotanshinone inhibits proliferation yet induces apoptosis by suppressing STAT3 signals in renal cell carcinoma.
Oncotarget,2017,8(30):50023-50033
|
被引
3
次
|
|
|
|
|
11.
Liu C. Cryptotanshinone induces ROS-mediated apoptosis in human gastric cancer cells.
Oncotarget,2017,8(70):115398-115412
|
被引
5
次
|
|
|
|
|
12.
Liu Y. Cryptotanshinone inhibites bladder cancer cell proliferation and promotes apoptosis via the PTEN/PI3K/AKT pathway.
J Cancer,2020,11(2):488-499
|
被引
5
次
|
|
|
|
|
13.
Ke F. Cryptotanshinone induces cell cycle arrest and apoptosis through the JAK2/STAT3 and PI3K/Akt/NFκB pathways in cholangiocarcinoma cells.
Drug Des Devel Ther,2017,11:1753-1766
|
被引
3
次
|
|
|
|
|
14.
Yang Y. Cryptotanshinone suppresses cell proliferation and glucose metabolism via STAT3/SIRT3 signaling pathway in ovarian cancer cells.
Cancer Med,2018,7(9):4610-4618
|
被引
2
次
|
|
|
|
|
15.
Park I J. Cryptotanshinone induces ER stress-mediated apoptosis in HepG2 and MCF7 cells.
Apoptosis,2012,17(3):248-257
|
被引
9
次
|
|
|
|
|
16.
Dixon S J. Ferroptosis: an iron-dendent form of of nopaptotic cell death.
Cell,2012,149(5):1060-1072
|
被引
678
次
|
|
|
|
|
17.
Cao J Y. Mechanisms of ferroptosis.
Cell Mol Life Sci,2016,73(11/12):2195-2209
|
被引
65
次
|
|
|
|
|
18.
Stockwell B R. Ferroptosis: a regulated cell death nexus linking metabolism,redox biology,and disease.
Cell,2017,171(2):273-285
|
被引
292
次
|
|
|
|
|
19.
Shi J. Cancer nanomedicine: progress,challenges and opportunities.
Nat Rev Cancer,2017,17(1):20-37
|
被引
120
次
|
|
|
|
|
20.
Okazaki S. Glutaminolysis-related genes determine sensitivity to xCT-targeted therapy in head and neck squamous cell carcinoma.
Cancer Sci,2019,110(11):3453-3463
|
被引
4
次
|
|
|
|
|
了解气象卫星更多信息，请访问